iSpecimen Appoints Robert Lim as CEO and Director
iSpecimen (NASDAQ: ISPC), an online marketplace connecting scientists with biospecimen providers, has appointed Robert Lim as CEO and director. Lim brings a diverse background as the principal and co-founder of De Novo Law , a Vancouver-based law firm specializing in corporate/commercial law. His experience includes founding Robert Bradley Lim Law and working in real estate and business law. Before his legal career, Lim worked in marketing, serving as a marketing coordinator for NEXT Environmental and founding a digital marketing agency. His approach focuses on helping businesses adapt, grow, and improve profitability through identifying opportunities and streamlining operations.
iSpecimen (NASDAQ: ISPC), un marketplace online che connette scienziati con fornitori di biospecimen, ha nominato Robert Lim come CEO e direttore. Lim porta un background diversificato come principale e co-fondatore di De Novo Law, uno studio legale con sede a Vancouver specializzato in diritto societario/commerciale. La sua esperienza include la fondazione di Robert Bradley Lim Law e l'attività nel settore immobiliare e nel diritto commerciale. Prima della sua carriera legale, Lim ha lavorato nel marketing, ricoprendo il ruolo di coordinatore marketing per NEXT Environmental e fondando un'agenzia di marketing digitale. Il suo approccio si concentra sull'aiutare le aziende ad adattarsi, crescere e migliorare la redditività attraverso l'individuazione di opportunità e l'ottimizzazione delle operazioni.
iSpecimen (NASDAQ: ISPC), un mercado en línea que conecta a científicos con proveedores de biospecimens, ha nombrado a Robert Lim como CEO y director. Lim aporta un fondo diverso como fundador y cofundador de De Novo Law, un bufete de abogados con sede en Vancouver que se especializa en derecho corporativo/comercial. Su experiencia incluye la fundación de Robert Bradley Lim Law y trabajo en derecho inmobiliario y empresarial. Antes de su carrera legal, Lim trabajó en marketing, desempeñándose como coordinador de marketing para NEXT Environmental y fundando una agencia de marketing digital. Su enfoque se centra en ayudar a las empresas a adaptarse, crecer y mejorar la rentabilidad mediante la identificación de oportunidades y la optimización de operaciones.
iSpecimen (NASDAQ: ISPC)는 과학자와 바이오 샘플 제공자를 연결하는 온라인 마켓플레이스로, 로버트 림을 CEO 및 이사로 임명했습니다. 림은 법인/상업 법률 전문의 밴쿠버에 위치한 법률 사무소 De Novo Law의 창립자이자 공동 창립자로서 다양한 배경을 가지고 있습니다. 그의 경험에는 로버트 브래들리 림 법률 사무소 설립과 부동산 및 비즈니스 법률 분야에서의 경력이 포함됩니다. 법조 경력 이전에, 림은 NEXT Environmental의 마케팅 코디네이터로 일하며 디지털 마케팅 에이전시를 설립하는 등 마케팅 분야에서 활동했습니다. 그의 접근방식은 기업들이 기회를 식별하고 운영을 간소화하여 적응하고 성장하며 수익성을 개선하도록 돕는 데 중점을 두고 있습니다.
iSpecimen (NASDAQ: ISPC), une place de marché en ligne connectant les scientifiques avec des fournisseurs de biospecimens, a nommé Robert Lim en tant que PDG et directeur. Lim a un parcours diversifié en tant que principal et co-fondateur de De Novo Law, un cabinet d'avocats basé à Vancouver spécialisé dans le droit des sociétés et commercial. Son expérience comprend la fondation de Robert Bradley Lim Law et un travail dans le droit immobilier et commercial. Avant sa carrière juridique, Lim a travaillé dans le marketing, occupant le poste de coordinateur marketing pour NEXT Environmental et fondant une agence de marketing numérique. Son approche se concentre sur l'assistance aux entreprises pour s'adapter, se développer et améliorer la rentabilité grâce à l'identification d'opportunités et à l'optimisation des opérations.
iSpecimen (NASDAQ: ISPC), ein Online-Marktplatz, der Wissenschaftler mit Anbietern von Biospecimens verbindet, hat Robert Lim zum CEO und Direktor ernannt. Lim bringt einen vielfältigen Hintergrund als Haupt- und Mitgründer von De Novo Law, einer in Vancouver ansässigen Anwaltskanzlei, die sich auf Unternehmens- und Handelsrecht spezialisiert hat. Zu seiner Erfahrung gehört die Gründung von Robert Bradley Lim Law sowie die Tätigkeit im Immobilien- und Wirtschaftsrecht. Vor seiner juristischen Karriere arbeitete Lim im Marketing, wo er als Marketingkoordinator für NEXT Environmental tätig war und eine digitale Marketingagentur gründete. Sein Ansatz konzentriert sich darauf, Unternehmen dabei zu helfen, sich anzupassen, zu wachsen und die Rentabilität zu steigern, indem er Chancen erkennt und die Abläufe optimiert.
- None.
- New CEO lacks direct experience in biospecimen or healthcare industry
- Appointment represents significant shift from legal/marketing background to healthcare technology sector
Woburn, Massachusetts--(Newsfile Corp. - December 12, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today that it has appointed Robert Lim as CEO and director.
Mr. Lim is the principal and co-founder of De Novo Law Corporation, a Vancouver-based law firm specializing in corporate/commercial law and civil litigation. With a forward-thinking approach to legal practice, Mr. Lim established De Novo Law Corporation to deliver innovative, client-focused solutions to a diverse range of businesses and individuals.
Before founding De Novo Law Corporation, Mr. Lim was the principal of Robert Bradley Lim Law Corporation, a legal practice he founded and led with a strong emphasis on providing personalized and strategic legal counsel. His journey into law was preceded by valuable experience at a prominent real estate and business law firm, where he honed his skills as a legal assistant, articling student. These experiences laid the groundwork for his deep understanding of complex legal and commercial matters.
Before embarking on his legal career, Mr. Lim brought a unique perspective to the profession through his background in marketing. He served as a marketing coordinator for NEXT Environmental, an environmental consulting firm, where he developed key skills in communication and strategic planning. He later founded a successful digital marketing agency, providing tailored marketing solutions to clients across British Columbia.
Drawing from his diverse professional background, Mr. Lim is committed to helping businesses thrive, as exemplified by his philosophy: "At the heart of any successful business is the ability to adapt, grow, and improve profitability. I'm passionate about working alongside organizations like iSpecimen to identify untapped opportunities, streamline operations, and ultimately enhance profit margins while driving sustainable growth."
Mr. Lim's multifaceted expertise in law and marketing enables him to approach legal challenges with creativity and a keen sense of strategy, making him a trusted advisor to his clients.
About iSpecimen
iSpecimen (NASDAQ: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," "believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company's filings with the SEC, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
Investor Contacts
info@ispecimen.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/233603
FAQ
What experience does Robert Lim bring to iSpecimen (ISPC) as new CEO?
How might Robert Lim's legal background benefit iSpecimen (ISPC)?
What is Robert Lim's business philosophy for leading iSpecimen (ISPC)?
What industries has Robert Lim worked in before joining iSpecimen (ISPC)?
